Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Assembly Biosciences, Inc.NASDAQ: ASMB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $1.12M rose 56.7% year over year, behind the +64.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 23.6% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.

Context

  • Stock-based compensation amounted to 6.5% of revenue in FY2025, down 4.5 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +56.7% toward the trailing-twelve-month pace of +64.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.12M-23.6% QoQ
Last fiscal yearDec 2025
$4.68M+49.9% YoY
LTMMar 2026
$5.08M+64.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.7%——
1 year+49.9%——
3-year CAGR-10.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
4.68M USD
Year-over-year change
+49.9%
4-year CAGR
-2.8%

Stock-Based Compensation vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 stock-based compensation of $5.08M is the 5th largest of the 6 companies compared; the peer median is $17.5M.
  • Its year-over-year change of +64.3% is the 2nd highest of 6, against a peer median of -32.6%.
  • Stock-based compensation amounts to 7.1% of revenue for ASMB, versus a peer median of 22.8%.
ASMB Competitors Peer median
Stock-Based Compensation for ASMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M +17.1%-21.7%53.5%
ABUSArbutus Biopharma CorporationLTM Mar 2026$18.43M +74.9%-1.1%9.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M -62.1%-23.7%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M -32.9%-11.7%22.8%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$5.08M +64.3%-10.8%7.1%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$1.19M -32.6%-22.8%—
Peer median (excluding ASMB) $17.5M-32.6%-21.7%22.8%

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Depreciation & Amortization466K498K450K129K129K
Deferred Income Tax(2.53M)0000
Stock-Based Compensation5.24M6.59M5.12M3.12M4.68M
Change in Working Capital(11.4M)(2.12M)76.34M(11.95M)(38.28M)
Accounts Receivables894K(608K)901K43K(974K)
Inventory00000
Accounts Payables(1.94M)(166K)(2.03M)124K586K
Other Working Capital(10.36M)(1.35M)77.47M(12.12M)(37.89M)
Other Non-Cash Items44.69M3.66M2.06M(2.24M)(1.5M)
Operating Cash Flow(93.4M)(84.46M)22.74M(51.12M)(41.09M)
Capital Expenditures(3.1M)(102K)(255K)(28K)(66K)
Acquisitions (Net)1.5M1.5M000
Purchases of Investments(160.45M)(27.58M)(133.92M)(90.5M)(232.18M)
Sales of Investments187.7M116.83M65.02M130.7M116.43M
Other Investing Activities857K024K02.35M
Investing Cash Flow26.52M90.64M(69.14M)40.17M(113.47M)
Debt Repayment00000
Common Stock Issued52.81M325K13.69M29.29M174.67M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities258K289K129K155K0
Financing Cash Flow53.06M614K13.82M29.45M174.67M
Effect of Forex Changes00000
Net Change in Cash(13.82M)6.79M(32.58M)18.5M20.11M
Free Cash Flow(96.49M)(84.57M)22.49M(51.15M)(41.16M)

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.